Edition:
United States

Syneron Medical Ltd (ELOS.OQ)

ELOS.OQ on NASDAQ Stock Exchange Global Select Market

10.85USD
26 May 2017
Change (% chg)

$-0.05 (-0.46%)
Prev Close
$10.90
Open
$10.88
Day's High
$10.88
Day's Low
$10.85
Volume
99,796
Avg. Vol
89,914
52-wk High
$11.43
52-wk Low
$6.21

ELOS.OQ

Chart for ELOS.OQ

About

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optica... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $382.27
Shares Outstanding(Mil.): 35.23
Dividend: --
Yield (%): --

Financials

  ELOS.OQ Industry Sector
P/E (TTM): 2,369.00 31.44 17.41
EPS (TTM): 0.00 -- --
ROI: 0.08 12.84 -5.42
ROE: 0.09 15.33 -4.68

BRIEF-Sand Grove Capital reports 5.2 pct stake in Syneron Medical

* Sand Grove Capital Management Llp reports 5.2 percent stake in Syneron Medical Ltd as of April 28 - SEC filing Source text - (http://bit.ly/2qZ8itX) Further company coverage:

May 10 2017

Apax to buy Israeli aesthetic device firm Syneron for $397 mln

TEL AVIV, April 3 British private equity firm Apax Partners has agreed to buy Israel's Syneron Medical Ltd, a non-surgical aesthetic device company, for $11.00 per share in cash, or a total of $397 million, the companies said on Monday.

Apr 03 2017

BRIEF-Syneron Candela reports agreement to be acquired by funds advised by Apax Partners

* Syneron Candela announces agreement to be acquired by funds advised by Apax Partners for $11.00/share in cash, representing an approximate value of $397 million

Apr 03 2017

Apax close to $500 mln deal to buy Israel's Syneron - reports

JERUSALEM, April 2 British private equity fund Apax Partners is close to finalizing a deal to buy Israel-based Syneron Medical, an aesthetic device company, for about $500 million, Israeli media reported on Sunday.

Apr 02 2017

More From Around the Web

Earnings vs. Estimates